Dyax Corporation (DYAX) - FREE Research Report

Kempner Thomas L who is Director at Dyax Corporation sold 400,000 shares at $8.37 on Dec. 6, 2013. Following this transaction, the Director owned 1.0 million shares meaning that the stake was reduced by 28.39% with the 400,000-share transaction.

The shares most recently traded at $8.14, down $0.23, or 2.81% since the insider transaction.

The average volume for Dyax Corporation has been 1.5 million shares per day over the past 30 days. Dyax Corporation has a market cap of $999.9 million and is part of the health care sector and drugs industry. Shares are up 137.36% year-to-date as of the close of trading on Friday.

Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas. It offers KALBITOR for the treatment of acute attacks of hereditary angioedema (HAE). Currently there are 4 analysts that rate Dyax Corporation a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DYAX - FREE

TheStreet Quant Ratings rates Dyax Corporation as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Get the full Dyax Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Community Banks Feeling Share-Price Pressure as Overexposure to CRE Loans Grows

Don't Forget, the Barrage of Bad News for Wells Fargo Will Soon Become a Distant Memory

Wall Street Week Ahead: Is Chaos the New Normal?

Community Banks' Increasing Real Estate Loans Exposure Problematic

Ignore Bullish Hype on Rate Hikes -- Book Profits on Community Banks Now